BIODEXA PHARMACEUTICALS-ADR (BDRX) Stock Price & Overview

NASDAQ:BDRXUS59564R8806

Current stock price

0.72 USD
-0.05 (-6.49%)
Last:

The current stock price of BDRX is 0.72 USD. Today BDRX is down by -6.49%. In the past month the price decreased by -38.38%. In the past year, price decreased by -95.65%.

BDRX Key Statistics

52-Week Range0.74 - 19.3
Current BDRX stock price positioned within its 52-week range.
1-Month Range0.74 - 1.42
Current BDRX stock price positioned within its 1-month range.
Market Cap
603.936K
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-20.85
Dividend Yield
N/A

BDRX Stock Performance

Today
-6.49%
1 Week
-15.73%
1 Month
-38.38%
3 Months
-78.84%
Longer-term
6 Months -88.35%
1 Year -95.65%
2 Years -99.81%
3 Years -99.21%
5 Years N/A
10 Years N/A

BDRX Stock Chart

BIODEXA PHARMACEUTICALS-ADR / BDRX Daily stock chart

BDRX Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to BDRX. When comparing the yearly performance of all stocks, BDRX is a bad performer in the overall market: 99.43% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BDRX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to BDRX. While BDRX seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BDRX Earnings

Next Earnings DateMay 12, 2026
Last Earnings DateN/A
PeriodQ2 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

BDRX Forecast & Estimates

7 analysts have analysed BDRX and the average price target is 183.6 USD. This implies a price increase of 25400% is expected in the next year compared to the current price of 0.72.


Analysts
Analysts85.71
Price Target183.6 (25400%)
EPS Next Y33.34%
Revenue Next YearN/A

BDRX Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

BDRX Financial Highlights

Over the last trailing twelve months BDRX reported a non-GAAP Earnings per Share(EPS) of -20.85. The EPS increased by 98.57% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-6.23M
Industry RankSector Rank
PM (TTM) N/A
ROA -42.01%
ROE -54.45%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%99.4%
Sales Q2Q%N/A
EPS 1Y (TTM)98.57%
Revenue 1Y (TTM)-100%

BDRX Ownership

Ownership
Inst Owners52.05%
Shares838.80K
Float838.80K
Ins Owners0.39%
Short Float %5.06%
Short Ratio0.14

About BDRX

Company Profile

BDRX logo image Biodexa Pharmaceuticals Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 13 full-time employees. The company went IPO on 2014-12-08. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.

Company Info

IPO: 2014-12-08

BIODEXA PHARMACEUTICALS-ADR

1 Caspian Point, Caspian Way

Abingdon OXFORDSHIRE GB

Employees: 13

BDRX Company Website

BDRX Investor Relations

Phone: 4401235888300

BIODEXA PHARMACEUTICALS-ADR / BDRX FAQ

What does BDRX do?

Biodexa Pharmaceuticals Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 13 full-time employees. The company went IPO on 2014-12-08. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.


What is the stock price of BIODEXA PHARMACEUTICALS-ADR today?

The current stock price of BDRX is 0.72 USD. The price decreased by -6.49% in the last trading session.


Does BDRX stock pay dividends?

BDRX does not pay a dividend.


What is the ChartMill rating of BIODEXA PHARMACEUTICALS-ADR stock?

BDRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


How is the valuation of BIODEXA PHARMACEUTICALS-ADR (BDRX) based on its PE ratio?

BIODEXA PHARMACEUTICALS-ADR (BDRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-20.85).


Would investing in BIODEXA PHARMACEUTICALS-ADR be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BDRX.